CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 65 enrolled
Drug / intervention
PLX3397 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01790503
NCT01790503Phase 2Completed
CompareCT.gov

An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Daiichi Sankyo·interventional·Posted Feb 13, 2013·Updated Jun 30, 2020

In Brief

A Phase 2 clinical trial evaluating PLX3397, Radiation Therapy, and 1 other intervention for Patients With Newly Diagnosed Glioblastoma. Completed, enrolled 65 participants across 9 sites.

Detailed Summary

The study objectives are to assess the potential for PLX3397 to improve the efficacy of standard of care radiation therapy (RT) + temozolomide in patients with newly diagnosed glioblastoma (GBM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPatients With Newly Diagnosed Glioblastoma
CountriesUnited States
CollaboratorsPlexxikon

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 13, 2013
Enrollment StartJul 18, 2013
Primary CompletionNov 3, 2017
Study CompletionMar 4, 2020
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 13.4 years ago

Interventions

PLX3397drug

Radiation Therapyradiation

Temozolomidedrug